Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER vs CEPHALOTHIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalothin is a first-generation cephalosporin with bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs).
1-2 g IV every 4-6 hours; maximum 12 g/day.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
Terminal elimination half-life: 0.5-1.0 hour in adults with normal renal function. In anuria, prolonged to 2.5-8 hours. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion). Minor biliary excretion (1-5%). Fecal elimination negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic